The clinical use of tumor markers in select cancers: Are you confident enough to discuss them with your patients?

Oncology Nursing Forum

Volumn 32, Issue 5, 2005, Pages 1013-1022

  Yamamoto, Deanna Sanchez ^a   Viale, Pamela Hallquist ^b   Roesser, Karen ^c   Lin, Albert ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b Camino Medical Group   (United States)

^c CJW Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BLADDER TUMOR; BREAST TUMOR; COLORECTAL TUMOR; FEMALE; HUMAN; LUNG TUMOR; MALE; METHODOLOGY; NEOPLASM; NURSING; ONCOLOGY NURSING; OVARY TUMOR; PANCREAS TUMOR; PROSTATE TUMOR; REVIEW;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; NEOPLASMS, GERM CELL AND EMBRYONAL; ONCOLOGIC NURSING; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33745338925     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.1013-1025     Document Type: Article

References (73)

1. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
2. Alper, O., Bergmann-Leitner, E.S., Bennett, T.A., Hacker, N.F., Stromberg, K., & Steuer-Stevenson, W.G. (2001). Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. Journal of the National Cancer Institute, 93, 1375-1384.
3. American Cancer Society. (2005a). Can prostate cancer be found early? Retrieved July 8,2005, from http://www.cancer.org/docroot/CRI/content/ CRI_2_4_3X_Can_prostate_cancer_be_found_early_36.asp?sitearea=
4. American Cancer Society. (2005b). Cancer facts and figures, 2005. Retrieved July 8, 2005, from http://www.cancer.org/downloads/STT/ CAFF2005f4PWSecured.pdf
5. American College of Preventive Medicine. (2001). Understanding prostate cancer screening: A statement from the American College of Preventive Medicine and Medem. Retrieved August 22, 2004, from http://www.acpm.org/pcscreening.htm
6. Balmer, L.L., & Greco, K.E. (2004). Prostate cancer recurrence fear: The prostate-specific antigen bounce. Clinical Journal of Oncology Nursing, 8, 361-366.
7. Barkin, J.S., & Goldstein, J.A. (2000). Diagnostic and therapeutic approach to pancreatic cancer. Biomedicine and Pharmacotherapy, 54, 400-409.
8. Bast, R.C., Jr., Ravdin, P., Hayes, D.F., Bates, S., Fritsche, H., Jr., Jessup, J.M., et al. (2001). 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1865-1878.
9. Brattstrom, D., Wester, K., Bergqvist, M., Hesselius, P., Malmstrom, P.U., Nordgren, K., et al. (2004). HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Acta Oncologica, 43, 80-86.
10. Bringhurst, C.B., & Amato, R. (1997). Medical oncology: A comprehensive review. Testicular cancer. Retrieved August 26, 2004, from http://www.cancernetwork.com/textbook/morev27.htm
11. Camilleri-Broet, S., Hardy-Bessard, A.C., Le Tourneau, A., Paraiso, D., Levrel, O., Leduc, B., et al. (2004). HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: A multicenter study of the GINECO group. Annals of Oncology, 15, 104-112.
12. Canil, C.M., & Tannock, I.F. (2002). Doctor's dilemma: Incorporating tumor markers into clinical decision-making. Seminars in Oncology, 29, 286-293.
13. Canto, E.I., & Slawin, K.M. (2002). Early management of prostate cancer: How to respond to an elevated PSA? Annual Review of Medicine, 53, 355-368.
14. Cheung, K.L., Graves, C.R., & Robertson, J.F. (2000). Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treatment Reviews, 26, 91-102.
15. Coldman, A.J., Phillips, N., & Pickles, T.A. (2003). Trends in prostate cancer incidence and mortality: An analysis of mortality change by screening intensity. Canadian Medical Association Journal, 168, 31-35.
16. Correlogic Systems, Inc. (2005). Frequently asked questions. Retrieved July 8,2005, from http://www.correlogic.com/faqs.htm
17. Doherty, A.P., Bower, M., & Christmas, T.J. (1997). The role of tumour markers in the diagnosis and treatment of testicular germ cell cancers. British Journal of Urology, 79, 247-252.
18. Duffy, M.J. (1999). CA 15-3 and related mucins as circulating markers in breast cancer. Annals of Clinical Biochemistry, 56(Pt. 5), 579-586.
19. Ebb, D.H., Green, D.M., Shamberger, R.C., & Tarbell, N.J. (2001). Cancer of childhood: Solid tumors of childhood. In V.T. DeVita, Jr., S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (6th ed., pp. 2169-2214). Philadelphia: Lippincott Williams and Wilkins.
20. Emens, L.A., & Davidson, N.E. (2003). The follow-up of breast cancer. Seminars in Oncology, 30, 338-348.
21. Ferrigno, D., Buccheri, G., & Giordano, C. (2003). Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer, 41, 311-320.
22. Fischbach, F. (2000). A manual of laboratory and diagnostic tests (6th ed.). Philadelphia: Lippincott Williams and Wilkins.
23. Fletcher, R.H. (1986). Carcinoembryonic antigen. Annals of Internal Medicine, 104, 66-73.
24. Frankel, S., Smith, G.D., Donovan, J., & Neal, D. (2003). Screening for prostate cancer. Lancet, 361, 1122-1128.
25. Gazzaniga, P., Gandini, O., Guiliani, L., Magnanti, M., Gradilone, A., Silvestri, I., et al. (2001). Detection of epidermal growth factor receptor mRNA in peripheral blood: A new marker of circulating neoplastic cells in bladder cancer patients. Clinical Cancer Research, 7, 577-583.
26. Glas, A.S., Roos, D., Deutekom, M., Zwinderman, A.H., Bossuyt, P.M., & Kurth, K.H. (2003). Tumor markers in the diagnosis of primary bladder cancer. A systematic review. Journal of Urology, 169, 1975-1982.
27. Goolsby, M.J. (2001). Use of PSA measurement in practice. Journal of the American Academy of Nurse Practitioners, 13, 246-248.
28. Guppy, A.E., & Rustin, G.J. (2002). CA125 response: Can it replace the traditional response criteria in ovarian cancer? Oncologist, 7, 437-443.
29. Gutman, S. (2002). Regulatory issues in tumor marker development. Seminars in Oncology, 29, 294-300.
30. Harish, K. (2000). Tumor markers. Retrieved October 29, 2003, from http://www.indiandoctors.com/bangalore/pap3.htm
31. Hensley, ML., Castiel, M., & Robson, M.E. (2001). Screening for ovarian cancer: What we know, what we need to know. Primary Care and Cancer, 21(1). Retrieved October 31, 2003, from http://www.cancernetwork.com/ journals/primary/p0101a.htm
32. Kim, J.E., Lee, K.T., Lee, J.K., Paik, S.W., Rhee, J.C., & Choi, K.W. (2004). Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. Journal of Gastroenterology and Hepatology, 19, 182-186.
33. Kulpa, J., Wojcik, E., Reinfuss, M., & Kolodziejski, L. (2002). Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clinical Chemistry, 48, 1931-1937.
34. Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996). Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Journal of Clinical Oncology, 14, 2584-2589.
35. Lamerz, R., Albrecht, W., Blalk, P., Duffy, M.J., Gerl, A., Malbohan, H.P., et al. (1999). European Group on Tumor Markers (EGTM) Recommendation 1999. Tumor markers in germ cell tumours. Retrieved November 14, 2003, from http://egtm.web.med.uni-muenchen.de/PPT/4/slide01.html
36. Ma, P.C., Blaszkowsky, L., Bharti, A., Ladanyi, A., Kraeft, S.K., Bruno, A., et al. (2003). Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Research, 23, 49-62.
37. Melissourgos, N., Kastrinakis, N.G., Davilas, I., Foukas, P., Farmakis, A., & Lykourinas, M. (2003). Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: Evaluation of an emerging tumor marker. Urology, 62, 362-367.
38. Merck & Co., Inc. (2004). Tumor immunodiagnosis. In The Merck manual of diagnosis and therapy (chap. 143). Retrieved from http://www.merck.com/mrkshared/mmanual/sectionll/chapter143/143d.jsp
39. Meyerhardt, J.A., & Mayer, R.J. (2003). Follow-up strategies after curative resection of colorectal cancer. Seminars in Oncology, 30, 349-360.
40. Mincey, B.A., Palmieri, F.M., & Perez, E.A. (2002). Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials. Oncologist, 7, 246-250.
41. Minghini, A., Weireter, L.J., Jr., & Perry, R.R. (1998). Specificity of elevated CA 19-9 levels in chronic pancreatitis. Surgery, 124, 103-105.
42. Mohr, S., Leikauf, G.D., Keith, G., & Rihn, B.H. (2002). Microarrays as cancer keys: An array of possibilities. Journal of Clinical Oncology, 20, 3165-3175.
43. Munster, P.N., & Norton, L. (2001). Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Research, 3, 361-364.
44. Mutlu, N., Turkeri, L., & Emerk, K. (2003). Analytical and clinical evaluation of a new urinary tumor marker: Bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. Clinical Chemistry and Laboratory Medicine, 41, 1069-1074.
45. Nordenson, N.J. (1999). Tumor markers. Retrieved October 16, 2003, from http://www.findarticles.com/cf_dls/g2601/0014/2601001410/print.jhtml
46. O'Dwyer, P.J., & Benson, A.B., III. (2002). Epidermal growth factor receptor-targeted therapy in colorectal cancer. Seminars in Oncology, 29(5, Suppl. 14), 10-17.
47. Pamies, R.J. (1996). Tumor markers. Cancer Detection and Prevention, 20(5). Retrieved August 26, 2004, from http://www.cancerprev.org/Journal/ Issues/20/5/602/1599
48. Perkins, G.L., Slater, E.D., Sanders, G.K., & Prichard, J.G. (2003). Serum tumor markers. American Family Physician, 68, 1075-1082.
49. Petricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., et al. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359, 572-577.
50. Petricoin, E.F., & Liotta, L.A. (2002). Proteomic analysis at the bedside: Early detection of cancer. Trends in Biotechnology, 20(12, Suppl.), S30-S34.
51. Pollack, A. (2004, February 3). New cancer test stirs hope and concern. New York Times, p. F1.
52. Ritter, C.A., & Arteaga, C.L. (2003). The epidermal growth factor receptortyrosine kinase: A promising therapeutic target in solid tumors. Seminars in Oncology, 30(1, Suppl. 1), 3-11.
53. Ross, J.S., & Gray, G.S. (2003). Targeted therapy for cancer: The HER-2/neu and Herceptin story. Clinical Leadership and Management Review, 17, 333-340.
54. San, F., Schlosser, W., Falkenreck, S., & Beger, H.G. (1996). CA 19-9 serum course and prognosis of pancreatic cancer. International Journal of Pancreatology, 20, 155-161.
55. Sanchez-Carbayo, M., Urrutia, M., Gonzalez de Buitrago, J.M., & Navajo, J.A. (2000). Evaluation of two new urinary tumor markers: Bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clinical Cancer Research, 6, 3585-3594.
56. Satoh, H., Ishikawa, H., Kurishima, K., Yamashita, Y.T., Ohtsuka, M., & Sekizawa, K. (2002). Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncology Reports, 9, 581-583.
57. Schrohl, A.S., Hollen-Andersen, M., Sweep, F., Schmitt, M., Harbeck, N., Foekens, J., et al. (2003). Tumor markers: From laboratory to clinical utility. Molecular and Cellular Proteomics, 2, 378-387.
58. Seidler, C.W., Conrad, A., Katipamula, R., & Mahmood, K. (2003). The role of carcinoembryonic antigen (CEA) in the diagnosis of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [Abstract 3550]. Proceedings of the American Society of Clinical Oncology, 22, 883.
59. Seleznick, M.J. (1992). Tumor markers. Primary Care, 19, 715-726.
60. Sell, S. (1990). Cancer markers of the 1990s: Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers. Clinics in Laboratory Medicine, 10, 1-37.
61. Shi, L. (2002). DNA microarray (genome chip): Monitoring the genome on a chip. Retrieved March 10, 2004, from http://www.gene-chips.com
62. Sonpavde, G., & Einhorn, L.H. (1999). What to do when you discover testicular cancer. Postgraduate Medicine, 105(4). Retrieved August 17, 2004, from http://www.postgradmed.com/issues/1999/04_99/sonpavde.htm
63. Sturgeon, C. (2002). Practice guidelines for tumor marker use in the clinic. Clinical Chemistry, 48, 1151-1159.
64. Swain, S.M., Wilson, J.W., Mamounas, E.P., Bryant, J., Wickerham, D.L., Fisher, B., et al. (2004). Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. Journal of the National Cancer Institute, 96, 516-523.
65. Thor, A. (2001). HER2 - A discussion of testing approaches in the USA. Annals of Oncology, 12(Suppl. 1), S101-S107.
66. Touchette, N. (2003). Diagnosing ovarian cancer by proteomics. Retrieved February 3, 2004, from http://www.genomenewsnetwork.org/articles/11_03/ ovarian_cancer.shtml
67. U.S. National Library of Medicine. (2004). Tumor markers, biological. Retrieved August 26, 2004, from the Penn State College of Medicine Web site: http://fred.hmc.psu.edu/ds/retrieve/fred/meshdescriptor/ D014408
68. Vaidya, A.P., & Curtin, J.P. (2003). The follow-up of ovarian cancer. Seminars in Oncology, 30, 401-412.
69. Vashi, A.R., & Oesterling, J.E. (1997). Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer. Mayo Clinic Proceedings, 72, 337-344.
70. von Eyben, F.E., Liu, F.J., Amato, R.J., & Fritsche, H.A. (2000). Lactate dehydrogenase isoenzyme 1 is the most important LD isoenzyme in patients with testicular germ cell tumor. Acta Oncologica, 39, 509-517.
71. Xiong, H.Q., & Abbruzzese, J.L. (2002). Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Seminars in Oncology, 29(5, Suppl. 14), 31-37.
72. Yamauchi, H., Stearns, V., & Hayes, D.F. (2001). When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. Journal of Clinical Oncology, 19, 2334-2356.
73. Zippe, C., Pandrangi, L., & Agarwal, A. (1999). NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. Journal of Urology, 161, 62-65.